Jenburkt Pharmaceuticals Ltd
BSE:524731
Cash Flow Statement
Cash Flow Statement
Jenburkt Pharmaceuticals Ltd
| Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
165
|
206
|
223
|
225
|
246
|
245
|
260
|
303
|
321
|
330
|
|
| Depreciation & Amortization |
20
|
19
|
19
|
21
|
23
|
23
|
23
|
24
|
27
|
30
|
|
| Other Non-Cash Items |
15
|
56
|
34
|
35
|
45
|
51
|
63
|
55
|
61
|
51
|
|
| Cash Taxes Paid |
58
|
70
|
76
|
78
|
82
|
79
|
83
|
104
|
134
|
128
|
|
| Cash Interest Paid |
3
|
3
|
3
|
4
|
5
|
7
|
2
|
(0)
|
3
|
3
|
|
| Change in Working Capital |
(6)
|
(50)
|
(182)
|
(239)
|
(143)
|
(180)
|
(265)
|
(167)
|
(129)
|
(129)
|
|
| Cash from Operating Activities |
195
N/A
|
231
+19%
|
94
-59%
|
42
-56%
|
171
+308%
|
138
-19%
|
81
-41%
|
215
+165%
|
279
+30%
|
282
+1%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(11)
|
(44)
|
(31)
|
1
|
(21)
|
(25)
|
(26)
|
(36)
|
(197)
|
(299)
|
|
| Other Items |
(176)
|
(125)
|
17
|
23
|
47
|
114
|
20
|
(77)
|
27
|
88
|
|
| Cash from Investing Activities |
(188)
N/A
|
(169)
+10%
|
(13)
+92%
|
23
N/A
|
26
+12%
|
88
+238%
|
(6)
N/A
|
(114)
-1 859%
|
(170)
-50%
|
(211)
-24%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
(145)
|
(145)
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
(5)
|
(8)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
|
| Cash Paid for Dividends |
0
|
(48)
|
(47)
|
(55)
|
(55)
|
(62)
|
(63)
|
(68)
|
(68)
|
(80)
|
|
| Other |
(2)
|
(2)
|
(3)
|
(4)
|
(5)
|
(7)
|
(2)
|
0
|
(3)
|
(3)
|
|
| Cash from Financing Activities |
(7)
N/A
|
(58)
-708%
|
(55)
+4%
|
(64)
-15%
|
(210)
-229%
|
(220)
-4%
|
(71)
+68%
|
(73)
-3%
|
(76)
-5%
|
(89)
-17%
|
|
| Change in Cash | |||||||||||
| Net Change in Cash |
(0)
N/A
|
4
N/A
|
25
+480%
|
1
-95%
|
(14)
N/A
|
7
N/A
|
5
-34%
|
29
+515%
|
32
+13%
|
(18)
N/A
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
183
N/A
|
187
+2%
|
63
-66%
|
42
-33%
|
149
+253%
|
113
-24%
|
56
-51%
|
179
+221%
|
82
-54%
|
(17)
N/A
|
|